Restricted accessResearch articleFirst published online 2026-3
How Can We Improve Subtyping of Colon Adenocarcinoma for Precision Oncology? Multi-Omics Consensus Clustering Reveals Immunologically Active and Therapeutically Distinct Molecular Groups
Colon adenocarcinoma (COAD) is a heterogeneous malignancy whose molecular complexity limits effective therapy. Existing transcriptome-based classifications capture only part of this diversity. To refine COAD stratification, we integrated genomic, epigenomic, and transcriptomic data from 297 The Cancer Genome Atlas patients. Ten complementary clustering algorithms were combined through a consensus ensemble framework to ensure robust and unbiased subtype discovery. The resulting molecular subtypes were characterized by genomic alterations, signaling pathways, tumor microenvironment features, and predicted therapeutic responses. As a result, four reproducible molecular subtypes (CS1–CS4) were identified. CS1 displayed enrichment of extracellular matrix organization and epithelial–mesenchymal transition signatures, suggesting invasive potential. CS2 exhibited transcriptional similarity to PD-1 responders, indicating potential benefit from immune checkpoint blockade. CS3 represented a mutation-driven subtype with frequent APC, TP53, and KRAS alterations and extensive copy number gains. CS4 showed the highest immune infiltration, elevated tumor mutational burden, and enhanced sensitivity to 5-fluorouracil and cetuximab. Validation across four independent cohorts confirmed the reproducibility of these subtypes. This integrative multi-omics framework refines the molecular taxonomy of COAD, revealing immunologically active and therapeutically distinct subgroups. The classification not only bridges genomic, epigenomic, and transcriptomic regulation but also provides a practical roadmap for precision oncology by linking molecular features to potential treatment strategies.
ArgaKY, SinhaR. Recent developments in cancer systems biology: Lessons learned and future directions. J Pers Med, 2021; 11(4):271; doi: 10.3390/jpm11040271
2.
ArgaKY. Interview with Prof. K. Yalçın Arga: A pioneer of multi-omics science and health care innovation. OMICS, 2019; 23(9):460–462; doi: 10.1089/omi.2019.0131
3.
BechtE, GiraldoNA, LacroixL, et al.Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol, 2016; 17(1):218; doi: 10.1186/s13059-016-1070-5
4.
BeklenH, YildirimE, KoriM, et al.Systems-level biomarkers identification and drug repositioning in colorectal cancer. World J Gastrointest Oncol, 2021; 13(7):638–661; doi: 10.4251/wjgo.v13.i7.638
5.
BeklenH, ArslanS, GulfidanG, et al.Differential interactome based drug repositioning unraveled abacavir, exemestane, nortriptyline hydrochloride, and tolcapone as potential therapeutics for colorectal cancers. Front Bioinform, 2021; 1:710591; doi: 10.3389/fbinf.2021.710591
6.
BinnewiesM, RobertsEW, KerstenK, et al.Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 2018; 24(5):541–550; doi: 10.1038/s41591-018-0014-x
7.
BudakB, ArgaKY. Tumor mutation burden as a cornerstone in precision oncology landscapes: Effect of panel size and uncertainty in cutoffs. OMICS, 2024; 28(4):193–203; doi: 10.1089/omi.2024.0015
8.
BuikhuisenJY, TorangA, MedemaJP. Exploring and modeling colon cancer inter-tumor heterogeneity: Opportunities and challenges. Oncogenesis, 2020; 9(7):66; doi: 10.1038/s41389-020-00250-6
9.
CalapricoA, et al.TCGAbiolinks: An R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res, 2016; 44(8):e71; doi: 10.1093/nar/gkv1507
10.
ChaliseP, FridleyBL. Integrative clustering of multi-level'omic data based on non-negative matrix factorization algorithm. PLoS One, 2017; 12(5):e0176278; doi: 10.1371/journal.pone.0176278
11.
ChhabraY, WeeraratnaAT. Fibroblasts in cancer: Unity in heterogeneity. Cell, 2023; 186(8):1580–1609; doi: 10.1016/j.cell.2023.03.016
12.
DienstmannR, VermeulenL, GuinneyJ, et al.Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer, 2017; 17(2):79–92; doi: 10.1038/nrc.2016.126
13.
DongreA, WeinbergRA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol, 2019; 20(2):69–84; doi: 10.1038/s41580-018-0080-4
14.
FangJ, ZhuQ, HongB, et al.An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. Cancer Cell Int, 2025; 25(1):383; doi: 10.1186/s12935-025-03996-4
15.
GalonJ, BruniD. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov, 2019; 18(3):197–218; doi: 10.1038/s41573-018-0007-y
16.
GeeleherP, CoxN, HuangRS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One, 2014; 9(9):e107468; doi: 10.1371/journal.pone.0107468
17.
GuinneyJ, DienstmannR, WangX, et al.The consensus molecular subtypes of colorectal cancer. Nat Med, 2015; 21(11):1350–1356; doi: 10.1038/nm.3967
18.
GulfidanG, TuranliB, BeklenH, et al.Pan-cancer mapping of differential protein-protein interactions. Sci Rep, 2020; 10(1):3272; doi: 10.1038/s41598-020-60127-x
19.
HanzelmannS, CasteloR, GuinneyJ. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 2013; 14(1):7; doi: 10.1186/1471-2105-14-7
HaunsbergerSJ, ConnollyNMC, PrehnJHM. miRNAmeConverter: an R/bioconductor package for translating mature miRNA names to different miRBase versions. Bioinformatics, 2017; 33(4):592–593; doi: 10.1093/bioinformatics/btw660
22.
HinoueT, WeisenbergerDJ, LangeCP, et al.Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res, 2012; 22(2):271–282; doi: 10.1101/gr.117523.110
23.
HoadleyKA, YauC, WolfDMet al.Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell, 2014; 158(4):929–944; doi: 10.1016/j.cell.2014.06.049
24.
HoshidaY. Nearest template prediction: A single-sample-based flexible class prediction with confidence assessment. PLoS One, 2010; 5(11):e15543; doi: 10.1371/journal.pone.0015543
25.
HoshidaY, BrunetJ-P, TamayoP, GolubTR, MesirovJP. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One, 2007; 2(11):e1195; doi: 10.1371/journal.pone.0001195
26.
HuangJ, OsarogiagbonRU, GirouxDJet al.The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2024; 19(5):766–785; doi: 10.1016/j.jtho.2023.10.012
27.
HudsonK, CrossN, Jordan-MahyN, LeylandR. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol, 2020; 11:568931; doi: 10.3389/fimmu.2020.568931
28.
JiangP, GuS, PanD, et al.Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med, 2018; 24(10):1550–1558; doi: 10.1038/s41591-018-0136-1
29.
KappAV, TibshiraniR. Are clusters found in one dataset present in another dataset? Biostatistics, 2007; 8(1):9–31; doi: 10.1093/biostatistics/kxj029
30.
KeumN, GiovannucciE. Global burden of colorectal cancer: Emerging trends, risk factors, and prevention strategies. Gastroenterology, 2019; 156(4):1238–1253; doi: 10.1038/s41575-019-0189-8
31.
KiranNS, YashaswiniC, MaheshwariR, et al.Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies. ACS Pharmacol Transl Sci, 2024; 7(4):967–990; doi: 10.1021/acsptsci.4c00008
32.
KoriM, OzdemirGE, ArgaKY, et al.A pan-cancer atlas of differentially interacting hallmarks of cancer proteins. J Pers Med, 2022; 12(11):1919; doi: 10.3390/jpm12111919
33.
LiY, MaY, WuZ, et al.Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: A systematic review and meta-analysis. Front Immunol, 2021; 12:751407; doi: 10.3389/fimmu.2021.751407
34.
LengauerC, KinzlerKW, VogelsteinB. Genetic instabilities in human cancers. Nature, 1998; 396(6712):643–649; doi: 10.1038/25292
35.
LiberzonA, BirgerC, ThorvaldsdóttirH, et al.The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst, 2015; 1(6):417–425; doi: 10.1016/j.cels.2015.12.004
36.
LlosaNJ, CruiseM, TamA, et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov, 2015; 5(1):43–51; doi: 10.1158/2159-8290.CD-14-0863
37.
LuP, WeaverVM, WerbZ. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol, 2012; 196(4):395–406; doi: 10.1083/jcb.201102147
38.
MaeserD, GruenerRF, HuangRS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform, 2021; 22(6); doi: 10.1093/bib/bbab260
39.
MarisaL, De ReynièsA, DuvalAet al.Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med, 2013; 10(5):e1001453; doi: 10.1371/journal.pmed.1001453
40.
MarusykA, JaniszewskaM, PolyakK. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell, 2020; 37(4):471–484; doi: 10.1016/j.ccell.2020.03.007
41.
LuX, MengJ, ZhouY, et al.MOVICS: An R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics, 2021; 36(22–23):5539–5541; doi: 10.1093/bioinformatics/btaa1018
42.
MayakondaA, LinDC, AssenovY, et al.Maftools: Efficient analysis, visualization and summarization of MAF files from large-scale cohort studies. Genome Res, 2018; 28(11):1747–1756; doi: 10.1101/gr.239244.118
43.
MengC, HelmD, FrejnoM, KusterB. moCluster: Identifying Joint Patterns Across Multiple Omics Data Sets. J Proteome Res, 2016; 15(3):755–765; doi: 10.1021/acs.jproteome.5b00824
44.
MermelCH, SchumacherSE, HillB, et al.GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol, 2011; 12(4):R41; doi: 10.1186/gb-2011-12-4-r41
MoQ, ShenR, GuoC, VannucciM, ChanKS, HilsenbeckSG. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics, 2018; 19(1):71–86; doi: 10.1093/biostatistics/kxx017
47.
MontiS, TamayoP, MesirovJ, GolubT. Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data. Machine Learning, 2003; 52(1–2):91–118; doi: 10.1023/A:1023949509487
48.
NewmanAM, SteenCB, LiuCLet al.Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol, 2019; 37(7):773–782; doi: 10.1038/s41587-019-0114-2, 31061481
49.
NguyenH, ShresthaS, DraghiciS, NguyenT. PINSPlus: a tool for tumor subtype discovery in integrated genomic data. Bioinformatics, 2019; 35(16):2843–2846; doi: 10.1093/bioinformatics/bty1049
OoftSN, WeeberF, DijkstraKK, et al.Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med, 2019; 11(513):eaay2574; doi: 10.1126/scitranslmed.aay2574
52.
OvermanMJ, LonardiS, WongKYM, et al.Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol, 2018; 36(8):773–779; doi: 10.1200/JCO.2017.76.9901
53.
ParkHS, Jun doY, HanCR, et al.Proteasome inhibitor MG132-induced apoptosis via ER stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human Jurkat T cells. Biochem Pharmacol, 2011; 82(9):1110–1125; doi: 10.1016/j.bcp.2011.07.085
54.
ParseghianCM, NapolitanoS, LoreeJM, KopetzS. Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res, 2019; 25(23):6899–6908; doi: 10.1158/1078-0432.CCR-19-0823
55.
PataiAV, MolnarB, KalmarA, et al.Role of DNA methylation in colorectal carcinogenesis. Dig Dis, 2012; 30(3):310–315; doi: 10.1159/000337004
56.
PowellDR, HuttenlocherA. Neutrophils in the Tumor Microenvironment. Trends Immunol, 2016; 37(1):41–52; doi: 10.1016/j.it.2015.11.008
57.
RahmanMR, IslamT, GovE, et al.Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: Insights from systems biology analysis. Medicina (Kaunas), 2019; 55(1):20; doi: 10.3390/medicina55010020
58.
RamazzottiD, LalA, WangBO, BatzoglouS, SidowA. Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival. Nat Commun, 2018; 9(1):4453; doi: 10.1038/s41467-018-06921-8
59.
RappoportN, ShamirR. NEMO: cancer subtyping by integration of partial multi-omic data. Bioinformatics, 2019; 35(18):3348–3356; doi: 10.1093/bioinformatics/btz058
60.
ReidJF, GariboldiM, SokolovaVet al.Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer, 2009; 48(11):953–962; doi: 10.1002/gcc.20697
61.
RitchieME, PhipsonB, WuD, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43(7):e47; doi: 10.1093/nar/gkv007
62.
SiegelRL, MillerKD, WagleNS, JemalA. Cancer statistics, 2023. CA Cancer J Clin, 2023; 73(1):17–48; doi: 10.3322/caac.21763
63.
SmithJJ, DeaneNG, WuFet al.Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology, 2010; 138(3):958–968; doi: 10.1053/j.gastro.2009.11.005
64.
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012; 487(7407):330–337; doi: 10.1038/nature11252
65.
TopalianSL, HodiFS, BrahmerJRet al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012; 366(26):2443–2454; doi: 10.1056/NEJMoa1200690
66.
ToyotaM, AhujaN, Ohe-ToyotaM, et al.CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A, 1999; 96(15):8681–8686; doi: 10.1073/pnas.96.15.8681
67.
TuranliB, KaragozK, GulfidanG, et al.A network-based cancer drug discovery: From integrated multi-omics approaches to precision medicine. Curr Pharm Des, 2018; 24(32):3778–3790; doi: 10.2174/1381612824666181106095959
68.
UllahI, YangL, YinFT, et al.Multi-omics approaches in colorectal cancer screening and diagnosis, recent updates and future perspectives. Cancers (Basel), 2022; 14(22):5545; doi: 10.3390/cancers14225545
69.
van de WeteringM, FranciesHE, FrancisJM, et al.Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015; 161(4):933–945; doi: 10.1016/j.cell.2015.03.053
70.
Vander HeidenMG, DeBerardinisRJ. Understanding the intersections between metabolism and cancer biology. Cell, 2017; 168(4):657–669; doi: 10.1016/j.cell.2016.12.039
71.
WangJ, CongY, TangB, et al.Integrative analysis of multi-omics data and gut microbiota composition reveals prognostic subtypes and predicts immunotherapy response in colorectal cancer using machine learning. Sci Rep, 2025; 15(1):25268; doi: 10.1038/s41598-025-08915-1
72.
WangW, KandimallaR, HuangH, et al.Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Semin Cancer Biol, 2019; 55:37–52; doi: 10.1016/j.semcancer.2018.05.002
73.
WangBO, MezliniAM, DemirFet al.Similarity network fusion for aggregating data types on a genomic scale. Nat Methods, 2014; 11(3):333–337; doi: 10.1038/nmeth.2810
74.
WuD, WangD, ZhangMQ, GuJ. Fast dimension reduction and integrative clustering of multi-omics data using low-rank approximation: application to cancer molecular classification. BMC Genomics, 2015; 16:1022; doi: 10.1186/s12864-015-2223-8
75.
YangG, JiL, LvC, et al.Integrated multi-omics analysis reveals PTM networks as key regulators of colorectal cancer progression and immune evasion. Discov Oncol, 2025; 16(1):1725; doi: 10.1007/s12672-025-03445-8
76.
YangW, SoaresJ, GreningerP, et al.Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery. Nucleic Acids Res, 2013; 41(Database issue):D955–D961; doi: 10.1093/nar/gks1111
77.
YoshiharaK, ShahmoradgoliM, MartínezE, et al.Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun, 2013; 4:2612; doi: 10.1038/ncomms3612
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
